Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Selexipag (Uptravi) is used for the treatment of pulmonary arterial hypertension (PAH), primarily to delay disease progression and reduce the risk of hospitalization.
• The safety profile of selexipag indicates that it has common tolerable side effects such as headache, nausea, and diarrhea in more than 70% of patients. It also demonstrates a similar safety profile to other oral therapies targeting the prostacyclin pathway, such as oral treprostinil.
• In terms of effectiveness, selexipag improves key indicators including the 6-minute walk distance (6-MWD), mean pulmonary arterial pressure (mPAP), and WHO functional class across various populations. This includes pediatric patients and those with Connective Tissue Disease-associated PAH (CTD-PAH).
• Different dosage levels—low, medium, or high—all show efficacy in improving health outcomes related to PAH. However, there is an increased likelihood of treatment discontinuation due to adverse events when compared to placebo.
• For specific population types, pediatric patients find this drug promising, showing potential for add-on therapy; while CTD-PAH patients have shown favorable effects on clinical outcomes from treatments that include selexipag.
• Eight studies providing comprehensive information about Uptravi's use in treating PAH were reviewed.